Alirocumab

Jump to navigation Jump to search
Pharmacologic interventions for PCSK9 Adapted from Journal of the American College of Cardiology, 62(16): 1401-1408[1]

For a review of all PCSK9 inhibitors please click here

WikiDoc Resources for Alirocumab

Articles

Most recent articles on Alirocumab

Most cited articles on Alirocumab

Review articles on Alirocumab

Articles on Alirocumab in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Alirocumab

Images of Alirocumab

Photos of Alirocumab

Podcasts & MP3s on Alirocumab

Videos on Alirocumab

Evidence Based Medicine

Cochrane Collaboration on Alirocumab

Bandolier on Alirocumab

TRIP on Alirocumab

Clinical Trials

Ongoing Trials on Alirocumab at Clinical Trials.gov

Trial results on Alirocumab

Clinical Trials on Alirocumab at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Alirocumab

NICE Guidance on Alirocumab

NHS PRODIGY Guidance

FDA on Alirocumab

CDC on Alirocumab

Books

Books on Alirocumab

News

Alirocumab in the news

Be alerted to news on Alirocumab

News trends on Alirocumab

Commentary

Blogs on Alirocumab

Definitions

Definitions of Alirocumab

Patient Resources / Community

Patient resources on Alirocumab

Discussion groups on Alirocumab

Patient Handouts on Alirocumab

Directions to Hospitals Treating Alirocumab

Risk calculators and risk factors for Alirocumab

Healthcare Provider Resources

Symptoms of Alirocumab

Causes & Risk Factors for Alirocumab

Diagnostic studies for Alirocumab

Treatment of Alirocumab

Continuing Medical Education (CME)

CME Programs on Alirocumab

International

Alirocumab en Espanol

Alirocumab en Francais

Business

Alirocumab in the Marketplace

Patents on Alirocumab

Experimental / Informatics

List of terms related to Alirocumab

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Alirocumab (REGN727 and SAR236553) is an investigational human monoclonal antibody that inhibits PCSK9 for the treatment of hypercholesterolemia.

Properties

Alirocumab is a human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that attaches to surface LDL receptors and triggers their degradation. This reduces the ability of hepatocytes to uptake LDL cholesterol and subsequently leads to increased levels of circulating LDL. By binding PCSK9, alirocumab inhibits LDL receptor destruction and increases the endocytosis of LDL from the circulation. Pre-clinical studies, and early clinical trials have shown the efficacy and safety of alirocumab in decreasing LDL cholesterol as an add-on agent or as monotherapy.

Major Trials

Phase II Trials

Safety and efficacy in primary hypercholesterolemia with ongoing stable atorvastatin therapy

This randomized, double-blind, placebo-controlled phase 2 trial of 183 patients with LDL-C ≥100 mg/dL on stable-dose atorvastatin for 6 or more weeks randomized patients to a 12 week treatment course in either one of 6 arms (1:1:1:1:1:1): subcutaneous (SC) placebo every 2 weeks, 50 mg SC alirocumab every 2 weeks, 100 mg SC alirocumab every 2 weeks, 150 mg SC alirocumab every 2 weeks, 200 mg SC alirocumab every 4 weeks alternating with placebo, or 300 mg SC alirocumab every 4 weeks alternating with placebo. Alirocumab demonstrated a significant dose-related reduction in serum LDL-C (40%, 64%, and 72% with 50, 100, and 150 mg respectively, and 43% and 48% with 200 and 300 mg respectively compared with 5% in placebo) with no major safety signals. [2]

Safety and efficacy in heterozygous familial hypercholesterolaemia with ongoing stable-dose statin with or without ezetimibe therapy

This randomized, double-blind, placebo-controlled phase 2 trial of 77 adults with heterozygous familial hypercholesterolaemia and LDL-C concentrations of ≥100 mg/dL or higher on stable diet and statin dose, with or without ezetimibe therapy were randomized (1:1:1:1:1) to 5 different treatment arms for 12 weeks: 150 mg SC alirocumab every 4 weeks, 200 mg SC alirocumab every 4 weeks, 300 mg SC alirocumab every 4 weeks, 150 mg SC alirocumab every 2 weeks, or SC placebo. Randomization was stratified by baseline use of ezetimibe. Alirocumab demonstrated a significant reduction in LDL-C at week 12 (28.9%, 31.5%, and 42.5% for the 150, 200, and 300 mg every 4 weeks respectively, and 67.9% for the 150 mg every 2 weeks dose, compared with 10.7% in the placebo arm) with no significant safety signal. There were no increases >3 x ULN in hepatic transaminases or creatine kinase (CK).[3]

Phase III Trials

References

  1. Urban, D.; Pöss, J.; Böhm, M.; Laufs, U. (2013). "Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis". J Am Coll Cardiol. 62 (16): 1401–8. doi:10.1016/j.jacc.2013.07.056. PMID 23973703. Unknown parameter |month= ignored (help)
  2. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA (2012). "Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy". J Am Coll Cardiol. 59 (25): 2344–53. doi:10.1016/j.jacc.2012.03.007. PMID 22463922.
  3. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R; et al. (2012). "Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial". Lancet. 380 (9836): 29–36. doi:10.1016/S0140-6736(12)60771-5. PMID 22633824.


Template:WikiDoc Sources